Xeris Biopharma Holdings (XERS) Revenue (2020 - 2025)
Historic Revenue for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $74.4 million.
- Xeris Biopharma Holdings' Revenue rose 3706.05% to $74.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $266.1 million, marking a year-over-year increase of 4204.5%. This contributed to the annual value of $203.1 million for FY2024, which is 2388.81% up from last year.
- Xeris Biopharma Holdings' Revenue amounted to $74.4 million in Q3 2025, which was up 3706.05% from $71.5 million recorded in Q2 2025.
- In the past 5 years, Xeris Biopharma Holdings' Revenue ranged from a high of $74.4 million in Q3 2025 and a low of $8.2 million during Q1 2021
- In the last 5 years, Xeris Biopharma Holdings' Revenue had a median value of $38.0 million in 2023 and averaged $38.6 million.
- Per our database at Business Quant, Xeris Biopharma Holdings' Revenue surged by 19214.72% in 2021 and then surged by 1230.96% in 2024.
- Xeris Biopharma Holdings' Revenue (Quarter) stood at $21.4 million in 2021, then skyrocketed by 54.67% to $33.1 million in 2022, then surged by 33.93% to $44.4 million in 2023, then surged by 35.39% to $60.1 million in 2024, then grew by 23.76% to $74.4 million in 2025.
- Its Revenue was $74.4 million in Q3 2025, compared to $71.5 million in Q2 2025 and $60.1 million in Q1 2025.